Myeloid-derived suppressor cells as osteoclast progenitors: A novel target for controlling osteolytic bone metastasis

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4606-4610

  Sawant, Anandi ^a   Ponnazhagan, Selvarangan ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RETINOIC ACID; TUMOR MARKER; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; BONE METASTASIS; BONE REGENERATION; BONE REMODELING; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER PROGNOSIS; CELL COUNT; CELL DIFFERENTIATION; CELL FATE; CELL FUNCTION; CELL INFILTRATION; CELL POPULATION; CELL PROLIFERATION; DISEASE CONTROL; DISTANT METASTASIS; EFFECTOR CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LUNG CARCINOMA; MULTIPLE MYELOMA; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PANCREAS CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL; SUPPRESSOR CELL; TARGET CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANIMALS; BONE NEOPLASMS; HUMANS; IMMUNE TOLERANCE; MYELOID CELLS; OSTEOCLASTS; STEM CELLS;

EID: 84881403359     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0305     Document Type: Review

References (24)

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
2. D'Amelio P, Fornelli G, Roato I, Isaia GC. Interactions between the immune system and bone. World J Orthop 2011;2:25-30.
3. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-36.
4. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
5. Sawant A, Deshane J, Jules J, Lee CM, Harris BA, Feng X, et al. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res 2012;73: 672-82.
6. Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A, et al. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol 2012;189:4258-65.
7. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-506.
8. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12: 253-68.
9. Danilin S, Merkel AR, Johnson JR, Johnson RW, Edwards JR, Sterling JA. Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology 2012;1:1484-94.
10. Zhuang J, Zhang J, Lwin ST, Edwards JR, Edwards CM, Mundy GR, et al. Osteoclasts in multiple myeloma are derived from Gr- 1+CD11b+myeloid-derived suppressor cells. PLoS One 2012;7: e48871.
11. Lippman ME. Breast cancer. In: Harrison's principles of internal medicine edn 16, part 7. New York: McGraw-Hill; 2005. p. 516-23.
12. Boyce BF, Rosenberg E, de Papp AE, Duong le T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur J Clin Invest 2012;42:1332-41.
13. Nakashima T, Takayanagi H. Osteoclasts and the immune system. J Bone Miner Metab 2009;27:519-29.
14. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-86.
15. Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000;96:1873-8.
16. Charles JF, Hsu LY, Niemi EC, Weiss A, Aliprantis AO, Nakamura MC. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest 2012;122:4592-605.
17. Papachristou DJ, Basdra EK, Papavassiliou AG. Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev 2010;32:611-36.
18. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF- 1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010;207: 2439-53.
19. Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D. Cell density mediated pericellular hypoxia leads to induction ofHIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene 2001;20:7624-34.
20. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007;179:977-83.
21. Kodumudi KN,WoanK, Gilvary DL, Sahakian E, Wei S, Djeu JY.Anovel chemoimmunomodulating property of docetaxel: suppression of myeloid- derived suppressor cells in tumor bearers. Clin Cancer Res 2010;16:4583-94.
22. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008;7:2160-9.
23. Gnant M, Dubsky P, Hadji P. Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res 2007;192: 65-91.
24. El-Mabhouh AA, Nation PN, Abele JT, Riauka T, Postema E, McEwan AJ, et al. A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases. Oncology Res 2011;19:287-95.